NKG2A & CD94

NKG2A & CD94 Informations sur la molécule

Nom anglais	NK cell lectin-like receptor subfamily C member 1	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6	Alias de la cible	CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	NK cell lectin-like receptor subfamily C member 1
Alias de la cible	CD159a，NKG2A，KLRC1，Killer Cell Lectin Like Receptor C1，Killer Cell Lectin-Like Receptor Subfamily C， Member 1，CD159 Antigen-Like Family Member A，NKG2-1/B Activating NK Receptor，NKG2-A/B-Activating NK Receptor，NK Cell Receptor A，NKG2-A/NKG2-B Type II Integral Membrane Protein，NKG2-A/B Type II Integral Membrane Protein，Natural Killer Group Protein 2，Natural Killer Cell Lectin，C-Lectin Type II Protein，CD159a Antigen，NKG2，NKG2-B，NKG2-A
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	6
Phase de R&D la plus avancée	Phase 3 Clinical

NKG2A & CD94 Liste de produits

Attribut
Protein (10)
Bibliothèque de produits
En ligne (10)
Espèces
Human (5)Cynomolgus (2)Mouse (3)
Étiquette
Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (3)His Tag (3)Fc Tag (2)His Tag & Avi Tag (1)
Marqueur
Unconjugated (6)Biotin-labeled (4)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT NC4-H5253	Human	HEK293	Human NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (MALS verified)	Ajouter au panier
HOT NC4-H52H3	Human	HEK293	Human NKG2A&CD94 Protein, His Tag, low endotoxin	Ajouter au panier
HOT NC4-H82E4	Human	HEK293	Biotinylated Human NKG2A&CD94 Protein, His,Avitag™	Ajouter au panier
HOT NC4-M82F5	Mouse	HEK293	Biotinylated Mouse NKG2A&CD94 Protein, Fc,Avitag™	Ajouter au panier
NC4-H5257	Human	HEK293	Human NKG2A&CD94 Protein, Fc Tag, low endotoxin (MALS verified)	Ajouter au panier
NC4-H82F5	Human	HEK293	Biotinylated Human NKG2A&CD94 Protein, Fc,Avitag™	Ajouter au panier
NC4-M5254	Mouse	HEK293	Mouse NKG2A&CD94 Protein, Fc Tag	Ajouter au panier
NC4-M52H9	Mouse	HEK293	Mouse NKG2A&CD94 Protein, His Tag	Ajouter au panier
NC4-C52H6	Cynomolgus	HEK293	Cynomolgus NKG2A&CD94 Protein, His Tag	Ajouter au panier
NC4-C82F7	Cynomolgus	HEK293	Biotinylated Cynomolgus NKG2A&CD94 Protein, Fc,Avitag™ (MALS verified)	Ajouter au panier

Quantité totale10

Demande de produit

NKG2A & CD94Contexte de la molécule

CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

NKG2A & CD94Alias de la molécule

NKG2A & CD94

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Monalizumab	NNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201	Phase 3 Clinical	Novo Nordisk A/S	Arthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms	Details
BMS-986315	BMS-986315	Phase 2 Clinical	Bristol-Myers Squibb Company	Carcinoma, Non-Small-Cell Lung; Solid tumours	Details
S-095029	S-095029	Phase 2 Clinical	Institut De Recherches Internationales Servier	Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms	Details
HY000102	HY-0102; HY-000102	Phase 2 Clinical	Shanghai HyaMab Biotech Co Ltd	Pancreatic Neoplasms; Solid tumours	Details
XB-628	XB628	Phase 1 Clinical	Exelixis Inc	Neoplasms; Solid tumours	Details
BRY-805	BRY805; BRY-805	Phase 1 Clinical	Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd	Solid tumours	Details